LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

70.19 -1.57

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

70.03

Maxim

72.08

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	24.818 49.052
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-63M 218M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+20.03% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	740M 8.4B
Deschiderea anterioară	71.76
Închiderea anterioară	70.19

Sentimentul știrilor

By Acuity

50%

154 / 344 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 iun. 2026, 23:36 UTC

Câștiguri

Correction to Oracle Reports Higher 4Q Profit Article

10 iun. 2026, 23:19 UTC

Acțiuni populare

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 iun. 2026, 23:09 UTC

Principalele dinamici ale pieței

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 iun. 2026, 23:04 UTC

Câștiguri

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 iun. 2026, 20:44 UTC

Principalele dinamici ale pieței

Caterpillar Raises Quarterly Dividend 8%

10 iun. 2026, 23:49 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Should Take No Options Off The Table

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 iun. 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 iun. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 iun. 2026, 23:46 UTC

Achiziții, Fuziuni, Preluări

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 iun. 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 iun. 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 iun. 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 iun. 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 iun. 2026, 21:57 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:52 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:35 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:22 UTC

Câștiguri

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 iun. 2026, 20:50 UTC

Market Talk

Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 iun. 2026, 20:39 UTC

Market Talk

Câștiguri

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 iun. 2026, 20:34 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 20:33 UTC

Câștiguri

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Global Equities Roundup: Market Talk

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

20.03% sus

Prognoză pe 12 luni

Medie 85.8 USD 20.03%

Maxim 96 USD

Minim 70 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

154 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.